Evidence map›Paper›PMID 29115981›Full record

ArticleBMC research notes2017

Hyperuricemia in type 2 diabetic model KK-A

Shin-Ichi Adachi, Fumiaki Yoshizawa, Kazumi Yagasaki

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Empagliflozin improves renal injury of diabetic nephropathy complicated with hyperuricemia through AMPK by promoting autophagy and inhibiting apoptosis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection.Pflugers Archiv : European journal of physiology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shin-Ichi AdachiCenter for Bioscience Research and Education, Utsunomiya University, Mine-machi 350, Utsunomiya, Tochigi, 321-8505, Japan.
Fumiaki YoshizawaCenter for Bioscience Research and Education, Utsunomiya University, Mine-machi 350, Utsunomiya, Tochigi, 321-8505, Japan.
Kazumi YagasakiCenter for Bioscience Research and Education, Utsunomiya University, Mine-machi 350, Utsunomiya, Tochigi, 321-8505, Japan. yagasaki@cc.tuat.ac.jp.ORCID http://orcid.org/0000-0002-9494-9887
Utsunomiya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHyperuricemia is recognized as a main cause of gout. Accumulating clinical evidence suggests that hyperuricemia is strongly associated with insulin resistance and abnormal glucose metabolism. However, there seem no proper animal models for investigating such associations. Ideal animal model is considered to be hyperuricemic as well as diabetic. Selecting the KK-A

resultsMale type 2 diabetic KK-A

Indexed as

Disease Models, AnimalInsulin ResistanceAnimalsDiabetes Mellitus, Type 2HyperuricemiaMaleMiceMice, Inbred C57BLUric AcidUric AcidHyperglycemiaHyperuricemiaInsulin resistanceKK-Ay/Ta mouse

Identifiers

PMID29115981
PMCPMC5678565
OpenAlexW2767403671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.